Anavex Life Sciences Corp.


Before the market opened on February 1, 2022, Anavex Life Sciences Corp. announced that a phase 3 trial of ANAVEX2-73 (blarcamesine) for Rett syndrome met primary and secondary endpoints. Following the announcement, several people on social media indicated that the primary and secondary endpoints were recently changed. STAT’s Adam Feuerstein tweeted, “Anavex changed the primary and secondary endpoints of this Rett study on Jan. 18, allowing it to claim success when the drug most likely failed.”

Shares of Anavex Life Sciences Corp stock dropped 16% in intraday trading on February 1, 2022.

Lead Plaintiff deadline
class period
Case Documents
No documents available. Contact us if you need a case document.